Current and future choices in endocrine therapy by Ellis, Matthew
A typical article on choices in endocrine therapy for breast
cancer generally focuses on a discussion of the use of an
adjuvant aromatase inhibitor versus tamoxifen, a comparison
between aromatase inhibitors, the value of ovarian suppres-
sion, the use of the steroidal oestrogen fulvestrant, or
possible roles for oestrogens and progestins as third-line
treatment in the management of advanced disease [1]. To
this menu one can now add the use of raloxifene as opposed
to tamoxifen as a chemoprevention agent in women at high
risk for the disease [2]. All of these options have been
examined in randomized clinical trials, but although positive
results have been observed, no recent studies have
demonstrated an impact on the disease that is close to that
seen when tamoxifen was compared with observation in the
worldwide overview of randomized tamoxifen trials in breast
cancer [3]. One can therefore reasonably conclude that a
major phase of drug development in breast cancer endocrine
therapy is drawing to a close. Although there may be
advances in oestrogen receptor (ER) targeting at the
margins, no major breakthrough is likely with the endocrine
studies that remain outstanding. The debate is therefore
beginning to refocus anew on how we might influence the
near constant relapse rate that continues more than a decade
after a diagnosis of ER-positive disease, despite the applica-
tion of our best ER targeting strategies.
So why is it that endocrine therapy does not cure all cases of
ER-positive breast cancer, and what are the research choices
that we should be making in order to design definitive clinical
trials that address this critical problem? The conventional
answer to this question is that ER-positive breast cancer is a
spectrum of tumour types with different patterns of somatic
mutations that influence ER function and reduce the efficacy
of endocrine agents [4]. The best support for this hypothesis
is the now definitive conclusion that HER2 gene amplification
reduces efficacy of endocrine approaches to ER-positive
breast cancer. In a variety of contexts, including endocrine
therapy for advanced disease, the adjuvant endocrine setting
and the neoadjuvant endocrine setting, the consistent pattern
of evidence demonstrates that ER-positive, HER2-positive
breast cancer does poorly in comparison with ER-positive,
HER2-negative disease [5]. Furthermore, treatment with
trastuzumab dramatically reduces the relapse rate for these
patients when combined with chemotherapy. So where will
we find the next example of a somatic mutation that can be
targeted in the remaining cases of poor prognosis ER-
positive, HER2-negative disease? The answer to this ques-
tion must evolve from a study of the breast cancer genome
using techniques such as array comparative genomic
hybridization and high-throughput sequencing [4].
Examples of other receptor tyrosine kinase amplification
events that might be relevant to the problem of endocrine
therapy resistance include fibroblast growth factor receptor
(FGFR)1 amplification, which appears to be relatively
common in ER-positive disease (frequency about 10%) and
insulin-like growth factor 1 receptor (IGF1R) amplification,
which is less common (frequency <5%), but it is of
considerable interest because of the new generation of
therapeutic IGF1R monoclonal antibodies. Downstream of
the receptor tyrosine kinases include gain-of-function
mutations in the α catalytic subunit of phosphoinositol-3-
kinase (PI3K), a AKT1 pleckstrin homology domain mutation,
loss of PTEN and amplification of RPS6KB1. As the clinical
phenotype of these mutations becomes clear, we can assess
their potential for pharmacological targeting. For example,
FGFR1 gene amplification was recently shown to be
associated with a poor prognosis [6]. In contrast, PIK3CA
mutation may be associated with good prognosis and
therefore is perhaps less valuable as a target [7].
Nonetheless, it would appear likely that PIK3CA mutations
will be present in patients with advanced disease, and
therefore direct inhibitors of PI3K might be of some value in
this setting.
At Washington University, and in other laboratories around
the world, we are beginning to develop a map of these
genomic changes within the context of several neoadjuvant
aromatase inhibitor trials in order to gain insights into the
effects of these mutations on sensitivity to endocrine therapy.
We term this project ‘The Luminal Breast Cancer Genome
Atlas’ [4]. The neoadjuvant approach is distinct from efforts
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that simply correlate baseline mutations with relapse-free
survival, because relapse data in adjuvant endocrine therapy
combine the effect of a mutation/amplification on both
prognosis and prediction. In contrast, in the neoadjuvant
setting, one can purely look at the impact of any given
mutation on endocrine therapy response as distinct from
prognosis. The neoadjuvant data will therefore give rise to
profiles that are different to, but complementary with, tumour
profiles that are trained on relapse data. In addition, an
understanding of the effects of mutations in the neoadjuvant
setting sets the scene (produces data useful for a power
calculation) for trials that partner endocrine agents with new
signal transduction agents, as and when these agents
become available for study in the early disease setting. We
would strenuously argue that all potential pairings of an
aromatase inhibitor with a new signaling agent should be
tested in a proof-of-principle study in the neoadjuvant setting
before a large-scale adjuvant clinical trial is undertaken [8]. A
comparison between the outcome of the P024 trial (which
compared letrozole and tamoxifen in the neoadjuvant setting
in about 300 patients) and that of the BIG (Breast
International Group) 1-98 trial (which conducted the same
comparison in about 8,000 patients) [9] shows that the
neoadjuvant study successfully predicted the superiority of
letrozole 5 years before the adjuvant result with 3% of the
study population. The on time accrual of the ongoing Z1031
trial (a neoadjuvant study that compares letrozole, anastrozole
and exemestane conducted by the American College of
Surgeons Oncology Group) underscores that these studies
can successfully be conducted in cancer clinical trial
cooperative groups, despite protocol requirements for fresh
tissue biopsies at diagnosis and surgery.
The hope for the future is that the next phase of endocrine
therapy choices will not be based on small incremental
benefits in a broad spectrum of ER-positive tumours, but
large benefits in sometimes rather small subgroups of
patients defined though the presence of a targetable somatic
mutation that interferes with endocrine therapy responsive-
ness. Improvements in the treatment of patients with ER-
positive, HER2-positive disease demonstrate that these
advances are possible, and we now have new leads from
genomic profiling that we should be able to take advantage of
in the near future.
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